Creatine: One of the Simplest (and Most Overlooked) Supports for the APOE4 Brain
If APOE4 is, at its core, an energy problem - then creatine deserves a permanent place in the conversation.
Most people still associate creatine with muscle and gym performance.
That’s not why I take it.
For me - and especially as an APOE4 (4/4) -t his is about brain energy, stability, and long-term resilience.
We know that APOE4 is linked to:
• impaired glucose utilization in the brain
• early mitochondrial inefficiency
• increased vulnerability to metabolic stress
And importantly - this starts decades before any clinical symptoms.
So the question becomes:
How do we support the brain’s energy system before it struggles?
Creatine is one of the most straightforward answers.
It helps regenerate ATP - the immediate energy currency our cells depend on - and acts as a kind of energy reserve system, especially in high-demand tissues like the brain.
In simple terms:
When energy demand spikes or when energy delivery isn’t optimal, Creatine helps bridge that gap. That’s highly relevant for APOE4.
There’s also evidence suggesting creatine may:
• support mitochondrial function
• reduce oxidative stress
• improve cognitive performance under fatigue or stress
• provide neuroprotective effects in aging populations
A couple of studies worth looking at if you want to go deeper:
• “Creatine Supplementation Improves Brain Performance”
• “Effects of Creatine on Brain Energy Metabolism and Cognitive Function”
(There are many more, but these are a good starting point.)
How I incorporate it
I keep this very simple.
• 5-10 grams daily
• mixed into water or yogurt
• no cycling, no loading phase
It’s tasteless, easy, and requires zero effort to maintain consistency.
Why it’s in my stack
Because this isn’t about chasing performance.
It’s about:
• stabilizing brain energy
• supporting mitochondrial function
• reducing vulnerability over time
Creatine is one of those rare additions that is:
✔ well studied
✔ inexpensive
✔ easy to take
✔ and mechanistically aligned with APOE4 risk
If APOE4 is a lifelong exercise in managing energy and resilience,
then supporting ATP availability is not optional - it’s foundational.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12089086/
https://www.tandfonline.com/doi/full/10.1080/19390211.2026.2616440#d1e1036
It’s very good. Crest-e got up to phase 3 in HD then was stopped early - I spoke to the team , they were shocked and felt some data had been misinterpreted and the trend they were seeing was good. Typically they had to pick well established ie bad and lots of damage from HD whereas the idea of adding a pre manifest / close to onset group was considered unviable in pre biomarker days, even now some researchers or funders think ( wrongly on my view) that you trial something on clearly affected people imagining that they are the worst and will show best improvement. That’s because I think they still think of ND illness as single worsening entity rather than an accelerating and multiplying cascade of pathologies. When the patient in a trial is even moderately advanced quite a few multiplying pathological processes have kicked off and a single agent will find it hard to put out all the forest fires, hence may not have an overall clear benefit. Whereas the modern democratisation of knowledge and supplement stacks and exercise diet etc etc that folks like you and Nick Norwich and many others do directly challenges the paradigm of the silver bullet that befuddles others. Good on you and all working together.
With creatine make sure it’s make sure it genuinely HPLC etc pharmaceutical grade . No contaminants needed please re brain.There is also another form with better absorption / bioavailability than mono which is a hydrochloride form available from USA direct from manufacturer, I can look that up from old info if wanted? ( no relation) . Knowledge is power.
That’s ’bad and lots of damage’ is referring to later established worse pathology HD patients in trials. The big thing is that research includes pre onset people in all ND stratified genetically and in every way as starting early as possible , whatever the age, is key. It still blows my mind that a generic trial in ‘Alzheimers’ is not always stratified by the obvious risk alleles.